Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGilead Sciences CDR (CAD Hedged)

Gilead Sciences CDR (CAD Hedged)

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
35.12 CAD 1.30 ( 3.84%)
Last update at 2026-11-04T20:46:00Z
VOLUME
3736
Market Cap
174329.60M
P/E
19.51

Momentum Score

…

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
34.40
Low
35.22
High
52 Week Price Range
19.56
Low
31.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Gilead Sciences CDR (CAD Hedged) provides Canadian-dollar-hedged exposure to Gilead Sciences, a large biopharmaceutical firm focused on antivirals, oncology and cell therapies with marketed medicines generating steady cash flow. Long-term growth may be supported by its HIV and antiviral franchises, expansion of oncology and cell-therapy offerings and ongoing clinical-stage programs, while the CAD hedge reduces currency volatility for Canadian investors.
Material risks include clinical or regulatory setbacks that could derail development efforts, patent expirations and intensified competition that may erode core product revenues, pricing and reimbursement pressure, and execution risk around launches and M&A.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
33.82
Dividend Yield
11.43%
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
4049.30%
Net Debt
17372.00M
ROCE
21.23%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax 9796.00M 690.00M 6859.00M 5814.00M
Minority interest 0.00M - - -
Net income 8510.00M 479.00M 5664.00M 4592.00M
Selling general administrative 5709.00M 5933.00M 5537.00M 5267.00M
Gross profit 23213.00M 22503.00M 21097.00M 21624.00M
Reconciled depreciation 2760.00M - - -
Operating income 10022.00M 1662.00M 7605.00M 7330.00M
Interest expense 1024.00M - - -
Tax provision 1286.00M 211.00M 1247.00M 1248.00M
Interest income 573.00M 970.00M 735.00M 1592.00M
Net interest income -675.00M - - -
Total revenue 29443.00M 28754.00M 27116.00M 27281.00M
Total operating expenses 19421.00M 27092.00M 19511.00M 19951.00M
Cost of revenue 6230.00M 6251.00M 6019.00M 5657.00M
Total other income expense net -1230.00M - - -
Net income from continuing ops 8510.00M - - -
Net income applicable to common shares 8510.00M 480.00M 5665.00M 4592.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 59023.00M 58995.00M 62125.00M 63171.00M
Intangible assets 16978.00M 19948.00M 26454.00M 28894.00M
Other current assets 1143.00M - - -
Total liab 36405.00M 39665.00M 39292.00M 41931.00M
Total stockholder equity 22618.00M 19330.00M 22833.00M 21240.00M
Other current liab 2243.00M - - -
Common stock - 1.00M 1.00M 1.00M
Capital stock 1.00M - - -
Retained earnings 13730.00M 11497.00M 16304.00M 15687.00M
Good will 8314.00M 8314.00M 8314.00M 8314.00M
Other assets 8239.00M 6146.00M 4792.00M 4800.00M
Cash 7564.00M - - -
Cash and equivalents 10605.00M 9991.00M 6085.00M 5412.00M
Total current liabilities 11813.00M 12004.00M 11280.00M 11237.00M
Net debt 17372.00M - - -
Short term debt - 0.00M 0.00M 0.00M
Short long term debt 2807.00M - - -
Other stockholder equity 22618.00M 132.00M 33.00M 35.00M
Property plant equipment 5606.00M 5414.00M 5317.00M 5475.00M
Total current assets 19886.00M 19173.00M 16085.00M 14443.00M
Long term investments 2974.00M - - -
Short term investments 2049.00M 0.00M 1179.00M 973.00M
Net receivables 4913.00M 4420.00M 4660.00M 4777.00M
Long term debt 22129.00M 24896.00M 23189.00M 22957.00M
Inventory 4368.00M 1710.00M 1787.00M 1507.00M
Accounts payable 715.00M - - -
Non currrent assets other 4845.00M - - -
Non current assets total 40681.00M - - -
Long term debt total - 24896.00M 23189.00M 22957.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -3163.00M - - -
Total cashflows from investing activities - -3449.00M -2265.00M -2466.00M
Net borrowings -1788.00M - - -
Total cash from financing activities -7745.00M -3433.00M -5125.00M -6469.00M
Net income 8510.00M 480.00M 5613.00M 4566.00M
Change in cash -2428.00M 3906.00M 673.00M 74.00M
Begin period cash flow 9991.00M - - -
End period cash flow 7564.00M - - -
Total cash from operating activities 10019.00M 10828.00M 8006.00M 9072.00M
Issuance of capital stock 408.00M - - -
Depreciation 2760.00M 381.00M 354.00M 323.00M
Other cashflows from investing activities - -2926.00M -1680.00M -1738.00M
Dividends paid -4003.00M 3918.00M 3809.00M 3709.00M
Change to inventory -1036.00M - - -
Change to account receivables -367.00M - - -
Sale purchase of stock -1922.00M -728.00M -768.00M -1087.00M
Other cashflows from financing activities - -281.00M -278.00M -173.00M
Capital expenditures 563.00M 523.00M 585.00M 728.00M
Change in working capital -3948.00M -880.00M -2302.00M -1763.00M
Stock based compensation 894.00M - - -
Other non cash items 1504.00M - - -
Free cash flow 9456.00M - - -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GILD
Gilead Sciences CDR (CAD Hedged)		 1.30
3.84%		 35.12 19.51 15.04 5.62 7.21 6.14 13.31
NOVO
Novo Nordisk CDR (CAD Hedged)		 0.92
5.27%		 18.37 3.31 3.54 1.10 1.74 3.88 7.66
MRK
Merck CDR (CAD Hedged)		 1.22
3.80%		 33.30 15.70 22.32 4.40 5.36 4.81 11.07
AMGN
Amgen CDR (CAD Hedged)		 1.29
3.78%		 35.38 24.19 15.65 5.06 21.36 6.30 13.69
SNY
Sanofi CDR (CAD Hedged)		 0.60
2.84%		 21.74 3.25 1.53 0.34 0.22 2.33 8.73

Profile*

Gilead Sciences CDR (CAD Hedged)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

333 Lakeside Drive, Foster City, CA, United States, 94404

650 574 3000

https://www.gilead.com

17600

Name Title Year Born
Mr. Daniel P. O'Day Chairman & CEO 1965
Mr. Andrew D. Dickinson Chief Financial Officer 1970
Ms. Johanna Mercier Chief Commercial Officer 1970
Ms. Erin Burkhart SVP, Controller & Principal Accounting Officer 1979
Ms. Jacquie Ross C.F.A. Senior Vice President of Treasury and Investor Relations NA
Ms. Keeley Wettan Executive VP and General Counsel of Legal & Compliance NA
Ms. Jyoti K. Mehra Executive Vice President of Human Resources 1976
Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation & Portfolio 1962
Dr. Flavius Martin M.D. Executive Vice President of Research NA
Ms. Janet Dorling Senior Vice President of Intercontinental Region & Global Patient Solutions 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…